Allyx Therapeutics, Inc.
PrivateLast Round
Series A
May 11, 2026
Total Funding Raised
$11.15M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Allyx Therapeutics, Inc. is a biotechnology company developing a first-in-class oral therapy to treat neurodegenerative diseases such as Alzheimer's and Parkinson's.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Allyx Therapeutics, Inc. Comparables
Compare Allyx Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Spinogenix, Inc. | 88% | |
| Annovis Bio, Inc. | 76% | |
| AlzeCure Pharma | 74% | |
Allyx Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 11, 2026 | ||||
| Seed Round | Mar 3, 2026 | ||||
| Grant | Oct 15, 2024 | ||||
| Series A | Jun 1, 2021 | ||||
| Early Funding | May 1, 2020 | ||||
Pre Seed | Apr 3, 2019 |
Key People
Founding team and executive leadership
Allyx Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Connecticut Innovations | Series A, Pre Seed, Early Funding |
| NIH RADx | Grant |
| Elm Street Ventures | Series A |
| Canaan Partners | Series A |
| Life Science Angels | Series A |
| Harrington Discovery Institute | Series A |
| Spring Mountain Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 11, 2026
$26.4M raised in an early stage VC round.
Allyx Therapeutics, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Allyx Therapeutics, Inc.'s valuation, stock price, and market status.